agenda
COVERING ALL THE IMPORTANT TOPICS
Amsterdam, 5 - 6 March 2025
Schedule
Create your personal agenda –check the favourite icon
Mar 57:30
Conference pass
Exhibitor Badge Collection
Keynotes
Exhibitor Badge Collection
Mar 58:00
Conference pass
Registration & Networking Meetings
Keynotes
Registration & Networking Meetings
Mar 58:55
Conference pass
Chair's Remarks
Keynotes
Chair's Remarks
Annette Powers, Senior Vice President, Global Market Access, Bristol Myers Squibb
Mar 59:00
Conference pass
Keynote presentation
Keynotes
Keynote presentation
Christoph Glaetzer, Chief Global Value and Access Officer, Johnson & Johnson
Mar 59:20
Conference pass
Title Sponsor Keynote Presentation
Keynotes
Session reserved for Title Sponsor
Mar 59:40
Conference pass
Pathways to overcoming access barriers in LMICs
Keynotes
Claus Runge, Senior Vice President, Global Head of Market Access, Public Affairs & Sustainability, Bayer
Mar 510:00
Conference pass
Keynote Sponsor Presentation - Lifescience Dynamics
Keynotes
Session Reserved for LIfescience Dynamics
Mar 510:20
Conference pass
Trends and opportunities in achieving health equity from the Access to Medicine Index
Keynotes
Jayasree Iyer, Chief Executive Officer, Access to Medicine Foundation
Mar 510:40
Conference pass
Morning Break
Keynotes
Morning Break in Exhibition Hall
Mar 511:00
Conference pass
Morning Break & Poster Sessions
Keynotes
Poster sessions in exhibition hall
Mar 511:40
Conference pass
Chair's Remarks
Real World Evidence & Data
Shuvayu Sen, Vice President, Head of Oncology, Center of Observational & Real-World Evidence, Merck & Co., Inc.
Mar 511:40
Conference pass
Chair's Remarks
Market Access
Reg Waldeck, Vice President, Oncology Market Access Strategy Leader, Bayer
Mar 511:40
Conference pass
Chair's Remarks
Pricing
Marina Faiella, Head, Forecasting and Business Analytics, Europe, BeiGene
Mar 511:40
Conference pass
Chair's Remarks
Pre-Launch Success
Gina Ewy, VP Global Market Access, Hansa Biopharma
Mar 511:40
Conference pass
Chair's Remarks
Reimbursement
Laurene Redding, Global Head, Value, Access & Pricing, BeiGene
Mar 511:40
Conference pass
Chair's Remarks
Rare Diseases
Toon Digneffe, Head, Public Affairs & Public Policy, Europe & Canada, Takeda
Mar 511:40
Conference pass
Chair's Remarks
Digital Transformation
Katja Berg, Global Director, Innovative Value and Access Strategy, Global Market Access and Pricing, BBU, AstraZeneca
Mar 511:40
Conference pass
Chair's Remarks
HTA
Marlene Gyldmark, Vice President, Head, Global Access Evidence, Idorsia
Mar 511:40
Conference pass
Chair's Remarks
Health Economics & Outcomes Research
Marlene Gyldmark, Vice President, Head, Global Access Evidence, Idorsia
Mar 511:45
Conference pass
Evidence generation in support of health equity
Real World Evidence & Data
Kinga Borsos, Vice President, Head of US HEOR, Boehringer Ingelheim
Mar 511:45
Conference pass
Evaluating value of medicines through carbon footprint avoidance in the patient treatment pathway
Market Access
Sally Chung, Vice President, Head of Market Access & Pricing Europe, GSK
Mar 511:45
Conference pass
Pricing innovations: art versus science
Pricing
Steve Sandor, Vice President, Market Access, Government Affairs and Trade, Paratek Pharmaceuticals , Inc.
Mar 511:45
Conference pass
Optimising long term launch commercial success with indication sequencing
Pre-Launch Success
Mar 511:45
Conference pass
The dilemma between costly products for low populations versus wider reimbursement for low budget impact
Reimbursement
Tomer Benzaken, Director, Head of Commercial Operations & Trade, Astellas
Mar 511:45
Conference pass
International access needs for orphan drugs: improving evidence and pricing strategies
Rare Diseases
Ulf Staginnus, Vice President, International Market Access & Pricing, Blueprint Medicines
Mar 511:45
Conference pass
Generative AI applications in market access and HEOR
Digital Transformation
Bill Malcolm, Executive Director, Global HEOR Economic & Predictive Modelling, BMS
Mar 511:45
Conference pass
SUSTAIN-HTA innovative methodologies: advancing national and European HTA practice
HTA
Mar 511:45
Conference pass
Improving gender disparities: advancing global health equity
Health Economics & Outcomes Research
Ipek Ozer-Stillman, Vice President, Global Head, Health Economics, Takeda
Mar 512:05
Conference pass
Sponsor presentation
Real World Evidence & Data
Reserved for sponsor
Mar 512:05
Conference pass
Session Reserved for EVERSANA
Market Access
Session reserved for sponsor
Mar 512:05
Conference pass
Sponsor presentation
Pricing
Session reserved for sponsor
Mar 512:05
Conference pass
Sponsor presentation
Pre-Launch Success
Session reserved for sponsor
Mar 512:05
Conference pass
Sponsor presentation
Reimbursement
Session reserved for sponsor
Mar 512:05
Conference pass
Sponsor presentation
Rare Diseases
Session reserved for sponsor
Mar 512:05
Conference pass
Session Reserved for Stratence Partners
Digital Transformation
Session reserved for sponsor
Mar 512:05
Conference pass
Session Reserved for Remap
HTA
Session reserved for sponsor
Mar 512:05
Conference pass
Session Reserved for Initiate
Health Economics & Outcomes Research
Session reserved for sponsor
Mar 512:25
Conference pass
RWE studies within registries: feasible or not?
Real World Evidence & Data
Helene Chevrou-Severac, Senior Director, RWE & Outcomes Centre of Excellence Head, Alexion – AstraZeneca Rare Disease
Mar 512:25
Conference pass
Novel medicines platform: what does this mean for EU access policy?
Market Access
Matt Slabbert, Vice President, Global Head of Pharma Public Affairs, Bayer
Mar 512:25
Conference pass
Challenges of international reference pricing
Pricing
Walmon Leal, Vice President, Head of Global Pricing, Tenders & Contract, Viatris
Mar 512:25
Conference pass
Deconstructing launches: learnings from mistakes and what works
Pre-Launch Success
Nidhi Dani, Director, Global Market Access, GSK
Mar 512:25
Conference pass
Improving access to innovative treatments across regions
Reimbursement
Fabian Schmidt, Global Head of Market Access, HEOR and Policy, Recordati Rare Diseases
Mar 512:25
Conference pass
Expectations for collaborations between patient groups and industry in appraisal processes
Rare Diseases
Robert Burley, Director, Care, Campaigns and Support, The Muscular Dystrophy U.K.
Mar 512:25
Conference pass
Where are we in AI for market access?
Digital Transformation
Marco Rauland, Vice President, Market Access, Strategy, Pricing and Analytics, Merck Group
Mar 512:25
Conference pass
Evidence and appraisal developments within HTA organisations: engaging stakeholders and policy makers
HTA
Goedele van Haasteren, Deputy Chief of the HTA department, Federal Office of Public Health, Switzerland
Mar 512:25
Conference pass
Improving HTA disparities for Middle East and North Africa
Health Economics & Outcomes Research
Lora Fleifel, Director, Market Access Operations, Oncology Europe, Merck
Mar 512:45
Conference pass
Session Reserved for Genesis Research
Real World Evidence & Data
Session reserved for sponsor
Mar 512:45
Conference pass
Session Reserved for Decisive Consulting
Market Access
Session reserved for sponsor
Mar 512:45
Conference pass
Session Reserved for Precision Advisors
Pricing
Session reserved for sponsor
Mar 512:45
Conference pass
Session Reserved for Stratenym
Pre-Launch Success
Session reserved for sponsor
Mar 512:45
Conference pass
Sponsor presentation
Reimbursement
Session reserved for sponsor
Mar 512:45
Conference pass
Sponsor presentation
Rare Diseases
Session reserved for sponsor
Mar 512:45
Conference pass
Session Reserved for Global Pricing Innovations
Digital Transformation
Session reserved for sponsor
Mar 512:45
Conference pass
Session Reserved for Visible Analytics
HTA
Session reserved for sponsor
Mar 512:45
Conference pass
Sponsor presentation
Health Economics & Outcomes Research
Session reserved for sponsor
Mar 513:05
Conference pass
Lunch
Keynotes
Lunch in Exhibition Hall
Mar 514:30
Conference pass
01 Real World Evidence & Data Panel – Advancing evidence generation using artificial intelligence
Real World Evidence & Data
Seema Sondhi, Head, Payer Value & Access, Takeda
Rossella Di Bidino, Head of HTA for AI Unit, Graduate School of Health Economics and Management ALTEMS
Rachel Studer, Global Evidence Executive Director, Oncology & Immunology, Novartis
Mar 514:30
Conference pass
01 Real World Evidence & Data Panel – Advancing evidence generation using artificial intelligence
Real World Evidence & Data
Seema Sondhi, Head, Payer Value & Access, Takeda
Rossella Di Bidino, Head of HTA for AI Unit, Graduate School of Health Economics and Management ALTEMS
Rachel Studer, Global Evidence Executive Director, Oncology & Immunology, Novartis
Mar 514:30
Conference pass
02 Market Access Panel – Anticipated impacts of the EU HTA on market access
Market Access
Lora Fleifel, Director, Market Access Operations, Oncology Europe, Merck
Patrick Hopkinson, Vice President, GHEOR, International Markets and HTA Strategy, Bristol-Myers Squibb
Bart Van Den Daele, Director, Market Access, Head of External Affairs, Gilead Sciences
Sandeep Kiri, Global Head, Health Economics and HTA Evidence, UCB
Marie Sanderson, Head of Value and Access, Innovative Medicine, Novartis
Mar 514:30
Conference pass
03 Pricing Panel - Reserved by Inbeeo
Pricing
Session reserved by Inbeeo
Mar 514:30
Conference pass
04 Market Access Panel – Challenges and opportunities for access to innovation in LMICs
Pre-Launch Success
Jorge Arellano, Vice President, Head of Intercontinental Markets, Market Access, Pricing, & Value Demonstration, Bristol Myers Squibb
Pauline L'Hénaff, Head of Industry Engagement, Access to Medicine Foundation
Mathieu Gilbert, Chief Operating Officer, Adocia
Korab Zuka, Vice President, Corporate Affairs, Purpose Communications and ESG, Bristol Myers Squibb
Diana Sinkevich, Head of Access, EU & International, Global Rare Diseases, Chiesi
Mar 514:30
Conference pass
05 Reimbursement Panel – The UK subscription model for antimicrobials: what’s next internationally?
Reimbursement
Warren Cowell, Director, Market Access UK, Shionogi Ltd
Mar 514:30
Conference pass
06 Rare Diseases Panel – Breaking down barriers for rare disease access: stakeholder perspectives
Rare Diseases
Philippe Ghyssels, Vice President, Global Public Affairs, Ipsen
Lorenzo Capretto, Market Access Lead EU&EM, Global Rare Disease, Chiesi Farmaceutici SpA
Luigi Angelillo, Director, Market Access EMEA, Argenx
Sandrine Ruiz, Senior Director, Market Access, Pricing & HEOR, Immunocore Ltd
Mar 514:30
Conference pass
07 Digital Transformation Panel – Patient-sourced data to accelerate digital transformation
Digital Transformation
Michela Pantaleoni, Chief Market Access Officer, Napo Therapeutics
Ipek Ozer-Stillman, Vice President, Global Head, Health Economics, Takeda
Dawn Ireland, President & Founder, CDH International
Mar 514:30
Conference pass
08 HTA Panel – Challenges for the implementation of the EU HTA
HTA
Josep M Guiu, Director, Pharmacy and Medicines Area, Consortium of health and social care of Catalonia
Gergana Zlateva, Vice President, Global Access & Pricing, Oncology, Pfizer
Kärt Veliste, Service Manager, Department of Medicines and Medical Devices, Tervisekassa Estonian Health Insurance Fund
Manel Juan, Head of Immunology Service, Hospital Clínic de Barcelona
Mar 514:30
Conference pass
09 Health Economics & Outcomes Research Panel – Parexel
Health Economics & Outcomes Research
Session reserved for sponsor
Mar 515:30
Conference pass
Chair's Remarks
Real World Evidence & Data
Tristan Gloede, Executive Director, Global Head of Market Access Retinal Health, Boehringer Ingelheim
Mar 515:30
Conference pass
Chair's Remarks
Market Access
Don Creighton, Executive Director, Market Access Pipeline and Readiness Lead, Regeneron
Mar 515:30
Conference pass
Chair's Remarks
Pricing
Astrid Buys, Global Head of Tenders & Pricing, Bavarian Nordic
Mar 515:30
Conference pass
Chair's Remarks
Pre-Launch Success
Julie Powell, Director, Patient Advocacy and Public Affairs, Pleco Therapeutics
Mar 515:30
Conference pass
Chair's Remarks
Reimbursement
Lisette Kaskens, Director Market Access, Ferring Pharmaceuticals
Mar 515:30
Conference pass
Chair's Remarks
Rare Diseases
Tomaso Piaggio, Head of Southern Cluster, International Market Access, Alnylam Pharmaceuticals
Mar 515:30
Conference pass
Chair's Remarks
Digital Transformation
Florence Robson-Barkats, Head of Patient Engagement, NHS Improvement
Mar 515:30
Conference pass
Chair's Remarks
HTA
Marnix Artz, Head, Patient Access, Pricing & Governmental Affairs, Merck Group
Mar 515:30
Conference pass
Chair's Remarks
Health Economics & Outcomes Research
Chair's Remarks
Maurice Driessen, Senior Director, Head of Inline Brands, GHEVO, Teva Pharmaceuticals
Mar 515:35
Conference pass
Evidence generation for HTA submissions
Real World Evidence & Data
Patricia Dorling, Vice President, Head, Global HEOR and Real World Evidence, Chiesi Group
Mar 515:35
Conference pass
Leading an innovative culture in access teams
Market Access
Robert Palmer, Head of Access, Oncology, Boehringer Ingelheim
Mar 515:35
Conference pass
Developing fair pricing to increase rare disease access in emerging countries
Pricing
Philippe Mourouga, Vice President, International Partner Markets, Biogen
Mar 515:35
Conference pass
The good, the bad and the ugly of launches: case studies and outcomes
Pre-Launch Success
Hannah Kurth, Founder and Managing Director, Pulse Edge
Mar 515:35
Conference pass
Leveraging current reimbursement pathways to enable more equitable access for antibiotics
Reimbursement
Jennifer Quinn, Head of Global Value and Access, Debiopharm International
Mar 515:35
Conference pass
Enabling earlier access for rare diseases: evaluating evidence for orphan drugs and payer challenges
Rare Diseases
Eunice Alvazzi, Head of Global Value & Access, Hematology, Nephrology & Neurology,, Alexion – AstraZeneca Rare Disease
Mar 515:35
Conference pass
AI in the service of digital transformation
Digital Transformation
Angie Kehagia, Deputy Director, Senior HTA, KiTEC King's Technology Evaluation Centre
Mar 515:35
Conference pass
How have HTA agencies evolved their methods over time? The importance of understanding HTA reforms
HTA
Martina Garau, Director, Office of Health Economics
Mar 515:35
Conference pass
From data to access: unlocking the patient journey
Health Economics & Outcomes Research
Thilo Schaufler, Global Head, Health Economics and Outcomes Research, CSL Vifor
Mar 515:55
Conference pass
Sponsor presentation
Real World Evidence & Data
Reserved for sponsor
Mar 515:55
Conference pass
Session reserved for Access Infinity
Market Access
Reserved for Access Infinity
Mar 515:55
Conference pass
Session Reserved for RxData
Pricing
Reserved for RxData
Mar 515:55
Conference pass
Session reserved for PDCI
Pre-Launch Success
Reserved for PDCI
Mar 515:55
Conference pass
Sponsor presentation
Reimbursement
Reserved for sponsor
Mar 515:55
Conference pass
Session Reserved for Pharma Business Partners
Rare Diseases
Reserved for Pharma Business Partners
Mar 515:55
Conference pass
Session Reserved for IQVIA
Digital Transformation
Reserved for IQVIA
Mar 515:55
Conference pass
Sponsor presentation
HTA
Reserved for sponsor
Mar 515:55
Conference pass
Sponsor presentation
HTA
Reserved for Sponsor
Mar 515:55
Conference pass
Sponsor presentation
Health Economics & Outcomes Research
Reserved for sponsor
Mar 516:15
Conference pass
RWE to support patient access: inequity of access across Denmark
Real World Evidence & Data
Trine Pilgaard, Director, Head of Market Access, Denmark and Iceland, Pfizer
Mar 516:15
Conference pass
Augmenting patient access through technology: democratising digital tools for market access
Market Access
Vijay Reddy, Chief Commercial Officer, Avinya Biotech
Mar 516:15
Conference pass
Pricing challenges and changing mindsets for high cost therapies
Pricing
Lara Pippo, Head of Market Access & Government Affairs, Italy, CSL Behring
Mar 516:15
Conference pass
Subnational reimbursement strategies for successful launches
Pre-Launch Success
Johnny Bane, Head of Market Access, Accord Healthcare
Mar 516:15
Conference pass
Advancing precision oncology across Europe: challenges for funding and reimbursement
Reimbursement
Matthijs Van Meerveld, Associate Vice President, Global Head of Access Policy & Patient Advocacy, Oncology, Menarini Stemline
Mar 516:15
Conference pass
Enhancing collaborations with industry: improving patient ac-cess early in the development cycle
Rare Diseases
Chantal van Litsenburg, Manager, Translational Effectiveness, Leiden University Medical Center (Netherlands)
Mar 516:15
Conference pass
Developing blockchain platforms for real world evidence generation in small population studies
Digital Transformation
Mar 516:15
Conference pass
Cost effectiveness and early access arrangements
HTA
Hans Severens, Independent HTA Expert, Severens HTA Consultancy
Mar 516:15
Conference pass
Societal perspectives in cost effectiveness analyses: a comprehensive assessment
Health Economics & Outcomes Research
Matthias Bischof, Senior Director, International Health Economics, Novartis
Mar 516:35
Conference pass
Networking Break
Keynotes
Networking break in exhibition hall
Mar 517:20
Conference pass
Chair's Remarks
Real World Evidence & Data
Chair's remarks
Mar 517:20
Conference pass
Chair's Remarks
Market Access
Michael Mueller, Head of Market Access, Western Europe, Sun Pharma
Mar 517:20
Conference pass
Chair's Remarks
Pricing
Chair's Remarks
Mar 517:20
Conference pass
Mar 517:20
Conference pass
Chair's Remarks
Reimbursement
Chair's Remarks
Manuela Machado, Global Payer Strategy Solutions Lead, UCB
Mar 517:20
Conference pass
Chair's Remarks
Rare Diseases
Loubna Ouriaghli, Head of Government Affairs and Policy, Ipsen
Mar 517:20
Conference pass
Chair's Remarks
Digital Transformation
Chair's Remarks
Mar 517:20
Conference pass
Chair's Remarks
HTA
Chair's Remarks
Mar 517:20
Conference pass
Chair's Remarks
Health Economics & Outcomes Research
Chair's Remarks
Mar 517:25
Conference pass
Sponsor presentation
Real World Evidence & Data
Reserved for sponsor
Mar 517:25
Conference pass
Sponsor presentation
Market Access
Reserved for sponsor
Mar 517:25
Conference pass
Sponsor presentation
Pricing
Reserved for sponsor
Mar 517:25
Conference pass
Sponsor presentation
Pre-Launch Success
Reserved for sponsor
Mar 517:25
Conference pass
Sponsor presentation
Reimbursement
Reserved for sponsor
Mar 517:25
Conference pass
Sponsor presentation
Rare Diseases
Reserved for sponsor
Mar 517:25
Conference pass
Sponsor presentation
Digital Transformation
Reserved for sponsor
Mar 517:25
Conference pass
Sponsor presentation
Digital Transformation
Reserved for sponsor
Mar 517:25
Conference pass
Sponsor presentation
HTA
Reserved for sponsor
Mar 517:25
Conference pass
Sponsor presentation
Health Economics & Outcomes Research
Reserved for sponsor
Mar 517:45
Conference pass
Risk aversion and health insurance: long terms perspectives on thresholds for real world evidence
Real World Evidence & Data
Joerg Mahlich, Market Access and Government Affairs Lead, Miltenyi Biomedicine GmbH
Mar 517:45
Conference pass
Early access programs: Italian experiences
Market Access
Silvia Miriam CAMMARATA, Senior Regulatory Affairs and Health Policy Specialist, AIFA Italian Medicine Agency
Mar 517:45
Conference pass
Challenges and opportunities for multi-indication pricing
Pricing
Julien Patris, Head of Patient Advocacy, Public Policy, Corporate Communications, EMEA, arGEN-X
Mar 517:45
Conference pass
Elevating market access to enable successful launches
Pre-Launch Success
Najib Slassi, Director, Global Product Strategy, Novartis
Mar 517:45
Conference pass
Reimbursement and negotiating access to orphan medications: regulatory and policy hurdles
Reimbursement
Mar 517:45
Conference pass
A global call to action for rare diseases
Rare Diseases
Jan Swiderski, Director, Head of Global Public Affairs and Advocacy, Ipsen
Philippe Ghyssels, Vice President, Global Public Affairs, Ipsen
Mar 517:45
Conference pass
Speaker presentation
Digital Transformation
Speaker presentation
Mar 517:45
Conference pass
Speaker presentation
HTA
Speaker presentation
Mar 517:45
Conference pass
Speaker presentation
Health Economics & Outcomes Research
Speaker presentation
Mar 518:05
Conference pass
Close of conference and drinks reception
Keynotes
Drink reception in exhibition hall
Create your personal agenda –check the favourite icon
Mar 68:55
Conference pass
Chair's Remarks
Keynotes
Keynote session
Mar 69:00
Conference pass
Industry commitments and collaborations to global health goals
Keynotes
Mar 69:20
Conference pass
Keynote presentation - Parexel
Keynotes
Keynote presentation - Parexel
Mar 69:40
Conference pass
Environmental sustainability and access to medicines – the way forward
Keynotes
Elena Tricca, Vice President, Global Market Access and Pricing, BioPharmaceuticals, AstraZeneca
Mar 610:00
Conference pass
Keynote presentation - Valid Insight
Keynotes
Keynote presentation - Valid Insight
Mar 610:20
Conference pass
Keynote panel discussion: Global healthcare reforms and their implications on local market access strategy
Keynotes
Arup Pramanik, Corporate Vice President, Head of Global Market Access, TA Inflammation, Boehringer Ingelheim
Mette Schrøder Hemels, Vice President, Global Payer Evidence, Portfolio Strategy, Access & Pricing, Novo Nordisk A/S
Laurent Carter, Senior Vice President, Head of Global Pricing, Bristol-Myers Squibb
Sandro Cesaro, Head of Europe Market Access & Pricing, AstraZeneca
Mar 610:20
Conference pass
Keynote panel discussion: Global healthcare reforms and their implications on local market access strategy
Keynotes
Laurent Carter, Senior Vice President, Head of Global Pricing, Bristol-Myers Squibb
Arup Pramanik, Corporate Vice President, Head of Global Market Access, TA Inflammation, Boehringer Ingelheim
Sandro Cesaro, Head of Europe Market Access & Pricing, AstraZeneca
Mette Schrøder Hemels, Vice President, Global Payer Evidence, Portfolio Strategy, Access & Pricing, Novo Nordisk A/S
Mar 611:55
Conference pass
Chair's Remarks
Real World Evidence & Data
Madhu Kabra, Global Director, Health Economics and Outcomes Research, MKGlobal
Mar 611:55
Conference pass
Chair's Remarks
Market Access
Lucia Paone, Senior Director, Market Access Product & Pipeline Strategy, Regeneron
Mar 611:55
Conference pass
Chair's Remarks
Pricing
Jiri Smejkal, Global Head of Pricing and Tender Excellence for PDT, Takeda
Mar 611:55
Conference pass
Chair's Remarks
Pre-Launch Success
Ana Filipa Alexandre, Former Vice President, Head of Pricing and Market Access, Santen
Mar 611:55
Conference pass
Chair's Remarks
Reimbursement
Mar 611:55
Conference pass
Chair's Remarks
Digital Transformation
Chair's Remarks
Mar 611:55
Conference pass
Chair's Remarks
HTA
Reserved for Norwegian Medical Products Agency
Mar 611:55
Conference pass
Chair's Remarks
Health Economics & Outcomes Research
Mar 612:00
Conference pass
Developing RWE platforms: allowing for high quality execution of evidence generation
Real World Evidence & Data
Tom Burke, Scientific Associate Vice President, CORE, MSD
Mar 612:00
Conference pass
Recent payer perspectives on novel end points
Market Access
Marie-Sharmila Blandino, Global Access Strategy Lead, Amgen
Mar 612:00
Conference pass
Early decision making for innovative medicine pricing
Pricing
Keir Woods, Vice President, Global Value Demonstration, Market Access & Pricing (GVAP), Oncology, Merck Group
Mar 612:00
Conference pass
Providing frameworks, incentives and tools to enable successful product development
Pre-Launch Success
Gorana Capkun, Vice President, Global Head of Patient Focused Real World Evidence, Merck Group
Mar 612:00
Conference pass
Innovative reimbursement schemes: uncertainties and performance indicators
Reimbursement
Ad Antonisse, Director, Market Access & Corporate Affairs, AstraZeneca
Mar 612:00
Conference pass
Bringing in patient voices to health authorities and industry
Rare Diseases
Sofiya Got, Chief Scientific Officer, Action Duchenne
Mar 612:00
Conference pass
Developing new HTA frameworks and methodologies for digital health technologies: the EDiHTA project
Digital Transformation
Emmanouil Tsiasiotis, Research Project Manager and Coordinator, EDiHTA
Wija Oortwijn, Chair of Appraisal Committee at ZINL & Assistant Professor, HTA, ZIN & Radboud University Medical Center
Mar 612:00
Conference pass
Decisional framework to accelerate integration of valuable innovations
HTA
Michele de Guise, President and Chief Executive Officer, INESSS
Mar 612:00
Conference pass
Simplifying targeted patient support to improve treatment outcomes and cost-effectiveness
Health Economics & Outcomes Research
Claire Everitt, Design Engineering Team Lead, IMI Project Leader, PFizer
Mar 612:20
Conference pass
Sponsor presentation
Real World Evidence & Data
Reserved for sponsor
Mar 612:20
Conference pass
Sponsor presentation
Market Access
Reserved for sponsor
Mar 612:20
Conference pass
Sponsor presentation
Pricing
Reserved for sponsor
Mar 612:20
Conference pass
Sponsor presentation
Pre-Launch Success
Reserved for sponsor
Mar 612:20
Conference pass
Sponsor presentation
Reimbursement
Reserved for sponsor
Mar 612:20
Conference pass
Sponsor presentation
Rare Diseases
Reserved for sponsor
Mar 612:20
Conference pass
Sponsor presentation
Digital Transformation
Reserved for Sponsor
Mar 612:20
Conference pass
Sponsor presentation
HTA
Reserved for sponsor
Mar 612:20
Conference pass
Chair's Remarks
Health Economics & Outcomes Research
Chair's Remarks
Mar 612:40
Conference pass
Impacts of integrated evidence approaches: measuring KPIs and patient benefits
Real World Evidence & Data
Elena Panitti, Global Director, Evidence Valuation and Enablement, Novartis
Mar 612:40
Conference pass
Applicability and generalizability of US community oncology EHR data to support robust global evidence dossiers
Market Access
Casey Rhode, Senior Vice President, Corporate Strategy, OneOncology
Mar 612:40
Conference pass
Implications of crossborder collaborations for pricing and procurement
Pricing
Neil Grubert, Global Market Access Expert, Independent
Mar 612:40
Conference pass
Deconstructing launches: learnings from patient journeys in rare diseases
Pre-Launch Success
Marianne Laouri, Executive Director, Global Asset Lead, Retinal Health, Boehringer Ingelheim
Mar 612:40
Conference pass
Translating clinical evidence to building pricing and reimbursement negotiation strategies: neuroeconomic approaches
Reimbursement
Alexander Wilke, Senior Director, Global Market Access and Pricing, Norgine
Mar 612:40
Conference pass
Drug-device combination products for orphan diseases: dealing with unmet needs and data uncertainty
Rare Diseases
Lotta Parviainen, Head of Global Market Access, Zambon France
Mar 612:40
Conference pass
Omni channel approaches to improve customer interactions through digital and other pathways
Digital Transformation
Aodan Tynan, Vice President, Global Market Access, Astellas
Mar 612:40
Conference pass
Speaker presentation for NICE
HTA
Reserved for NICE
Mar 612:40
Conference pass
Speaker presentation
Health Economics & Outcomes Research
Speaker presentation
Mar 613:00
Conference pass
RWE: when does it move the needle?
Real World Evidence & Data
Reserved for sponsor
Geraldine Rylander, Director, Global Market Access, Psychiatry & Pipeline, Lundbeck
Mar 613:00
Conference pass
Session Reserved for LCP
Market Access
Reserved for LCP
Mar 613:00
Conference pass
Session Reserved for Stratence Partners
Pricing
Session Reserved for Stratence Partners
Mar 613:00
Conference pass
Session Reserved for AMICULUM
Pre-Launch Success
Reserved for sponsor
Mar 613:00
Conference pass
Sponsor presentation
Reimbursement
Reserved for sponsor
Mar 613:00
Conference pass
Sponsor presentation
Rare Diseases
Reserved for sponsor
Mar 613:00
Conference pass
Sponsor presentation
Digital Transformation
Reserved for sponsor
Mar 613:00
Conference pass
Session Reserved for AESARA
HTA
Reserved for AESARA
Mar 613:00
Conference pass
Sponsor presentation
Health Economics & Outcomes Research
Reserved for sponsor
Mar 613:20
Conference pass
Lunch
Keynotes
Lunch in exhibition hall
Mar 614:45
Conference pass
01 Real World Evidence & Data Panel – From data to decisions: harnessing evidence for seamless product launches
Real World Evidence & Data
Sylvie Greneche, Head of Global Market Access, General Medicines, Sanofi
Jolanda Koenders, Head of New Product Planning, Central Southeast Europe, Takeda
Mar 614:45
Conference pass
02 Market Access Panel – Improving access to gene therapies: challenges and key learnings
Market Access
Loic Gauthier, Director, Market Access and Pricing, Intercontinental Region, CSL Behring
Andrew Olaye, Head of EMEA Market Access, Orchard Therapeutics Ltd
Günter Harms, Senior Director, Patient Access, Germany, Austria, Switzerland, Novartis Gene Therapies
Paolo Morgese, Vice President, Public Affairs, Europe, Alliance for Regenerative Medicine
Stephen Connell, Senior Director, Global Pricing & Market Access - Gene Therapy, Pfizer
Mar 614:45
Conference pass
03 Pricing Panel – Value based healthcare in theory and practice: challenges for pricing
Pricing
Emanuele Degortes, Vice President, Global Head of Access Policy and Patient Advocacy, Menarini
Jose Aragunde, Value and Pricing Strategy Lead, Market Access, Novartis
Chris Prins, Policy Advisor Expensive Medicines, Zorgverzekeraars Nederland
Igor Solev, Global Head, Market Access, Policy & External Payer Affairs, Abbott Laboratories
Mar 614:45
Conference pass
04 Pre-launch Success Panel – Access Infinity
Pre-Launch Success
Session Reserved for Access Infinity
Mar 614:45
Conference pass
04 Pre-launch Success Panel – Access Infinity
Pre-Launch Success
Session Reserved for Access Infinity
Mar 614:45
Conference pass
05 Reimbursement Panel – Sustainability of healthcare: reimbursement driven by affordability constraints
Reimbursement
Daniel Jackson, Global Head, Market Access Policy, UCB
Marie-Monique de Molliens, Global Market Access Horizon Scanning Senior Director, Sanofi
Chiara Brouns, Strategic purchaser, Zorgverzekeraars Nederland
Mary Lynne van Poelgeest-Pomfret, President, World Federation for Incontinence and Pelvic Problems (WFIPP)
Marta Andreykiv, Head of Market Access Europe, Viatris
Mar 614:45
Conference pass
06 Rare Diseases Panel – Delivering pharmaceutical innovation across the globe: WHO Europe & the Novel Medicines Platform
Rare Diseases
Thomas Bols, Head of Government Affairs and Patient Advocacy, EMEA, PTC Therapeutics
Jean Christophe Goirand, Senior Director, Global Head Market Access & Pricing, Essential Pharma
Thomas Grub, Senior Expert, Global Pricing and Market Access, Medac GmbH
Mar 614:45
Conference pass
07 Digital Transformation Panel - Reserved for sponsor
Digital Transformation
Reserved for sponsor
Mar 614:45
Conference pass
08 HTA Panel – Rethinking added values of AI in HTA: debunking myths
HTA
Mar 614:45
Conference pass
09 Health Economics & Outcomes Research Panel – What are the next steps for generative AI in HEOR?
Health Economics & Outcomes Research
Oresta Piniazhko, Director of HTA Department, State Expert Centre of the Ministry of Health of Ukraine
Alen Marijam, Senior Director, Vaccines, HEOR and Epidemiology Lead, Europe, GSK
Mar 615:45
Conference pass
Chair's Remarks
Real World Evidence & Data
Chair's Remarks
Mar 615:45
Conference pass
Chair's Remarks
Market Access
Chair's Remarks
Mar 615:45
Conference pass
Chair's Remarks
Pricing
Chair's Remarks
Mar 615:45
Conference pass
Chair's Remarks
Pre-Launch Success
Chair's Remarks
Mar 615:45
Conference pass
Chair's Remarks
Reimbursement
Chair's Remarks
Mar 615:45
Conference pass
Chair's Remarks
Rare Diseases
Chair's Remarks
Mar 615:45
Conference pass
Chair's Remarks
Digital Transformation
Chair's Remarks
Mar 615:45
Conference pass
Chair's Remarks
HTA
Chair's Remarks
Mar 615:45
Conference pass
Chair's Remarks
Health Economics & Outcomes Research
Chair's Remarks
Mar 615:50
Conference pass
Speaker presentation
Real World Evidence & Data
Speaker presentation
Mar 615:50
Conference pass
Commercially sustainable access: expanding access in LMICs
Market Access
Speaker presentation
Ana Plata, Head of Global Access, Respiratory & Immunology, AstraZeneca
Mar 615:50
Conference pass
Speaker presentation
Pricing
Speaker presentation
Mar 615:50
Conference pass
Early development plans: determining scenarios for value and outcomes in Europe
Pre-Launch Success
Steven Flostrand, Executive Director, Value, Access & Pricing, Incyte Corp.
Mar 615:50
Conference pass
Speaker presentation
Reimbursement
Speaker presentation
Mar 615:50
Conference pass
Challenges and opportunities to launching two assets in one rare disease indication
Rare Diseases
Speaker presentation
Sebastian Kessel, Senior Director, Head of Market Access & Public Affairs, Germany, UCB
Mar 615:50
Conference pass
Speaker presentation
Digital Transformation
Speaker presentation
Mar 615:50
Conference pass
Speaker presentation
HTA
Speaker presentation
Mar 615:50
Conference pass
Speaker presentation
Health Economics & Outcomes Research
Speaker presentation
Mar 616:10
Conference pass
Sponsor presentation
Real World Evidence & Data
Reserved for sponsor
Mar 616:10
Conference pass
Session Reserved for IPSOS
Market Access
Reserved for IPSOS
Mar 616:10
Conference pass
Sponsor presentation
Pricing
Reserved for sponsor
Mar 616:10
Conference pass
Sponsor presentation
Pre-Launch Success
Reserved for sponsor
Mar 616:10
Conference pass
Sponsor presentation
Reimbursement
Reserved for sponsor
Mar 616:10
Conference pass
Sponsor presentation
Rare Diseases
Reserved for sponsor
Mar 616:10
Conference pass
Sponsor presentation
Digital Transformation
Reserved for sponsor
Mar 616:10
Conference pass
Sponsor presentation
HTA
Reserved for sponsor
Mar 616:10
Conference pass
Sponsor presentation
Health Economics & Outcomes Research
Reserved for sponsor
Mar 616:30
Conference pass
Speaker presentation
Real World Evidence & Data
Speaker presentation
Mar 616:30
Conference pass
Speaker presentation
Market Access
Speaker presentation
Mar 616:30
Conference pass
Speaker presentation
Pricing
Speaker presentation
Mar 616:30
Conference pass
Speaker presentation
Pre-Launch Success
Speaker presentation
Mar 616:30
Conference pass
Speaker presentation
Reimbursement
Speaker presentation
Mar 616:30
Conference pass
Speaker presentation
Rare Diseases
Speaker presentation
Mar 616:30
Conference pass
Speaker presentation
Digital Transformation
Speaker presentation
Mar 616:30
Conference pass
Speaker presentation
HTA
Speaker presentation
Mar 616:30
Conference pass
Speaker presentation
Health Economics & Outcomes Research
Speaker presentation
last published: 19/Jun/24 09:45 GMT
Get Involved
Sponsorship & Exhibition Sales
David Boore
david.boore@terrapinn.com
+44 20 8164 3052
Conference Production
George Mullens
george.mullens@terrapinn.com
+44 20 8164 3940
Marketing Opportunities
Karen Duncan
karen.duncan@terrapinn.com
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events